在晚期黑色素瘤患者中,印梅他辛加拉尼提丁对高剂量互白素-2的作用
W C Mertens1, V H Bramwell, F Gwadry-Sridhar
1Department of Medical Oncology, London Regional Cancer Centre, Canada.
Lancet (London, England)
|August 15, 1992
概括
在晚期黑色素瘤患者中,慢性印梅他辛和拉尼蒂丁治疗显示出有前途的结果. 这些药物,单独或与IL-2一起,诱导了客观反应,这表明IL-2治疗之外的关键作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 临床前模型表明,结合的印美他辛和互白素2 (IL-2) 消除了实验性黑色素瘤转移.
- 晚期黑色素瘤仍然是一个重大的临床挑战,需要新的治疗策略.
研究的目的:
- 评估印梅他辛和拉尼蒂丁的疗效,有或没有IL-2,在患有晚期黑色素瘤的患者.
- 为了确定印梅他辛和拉尼蒂丁是否有助于以前仅归因于IL-2的治疗反应.
主要方法:
- 进行了一项II期临床试验,涉及到晚期黑色素瘤患者.
- 在开始IL-2治疗之前,至少在一周内服用了印梅他辛和拉尼蒂丁.
主要成果:
- 在3名被评估的患者中观察到客观反应.
- 其中两种客观反应发生在单独治疗拉尼蒂丁和印莫他之前,在IL-2注射之前.
结论:
- 印米他辛和拉尼蒂丁可能在晚期黑色素瘤患者的治疗反应中发挥重要作用.
- 这些发现表明,归因于IL-2的反应可能部分是由于同步使用印米他辛和拉尼蒂丁.
相关概念视频
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...